New Findings in Live, Attenuated Hepatitis A Vaccine Development

✍ Scribed by P. J. Provost; R. J. Gerety; M. R. Hilleman; W. J. McAleer; E. M. Scolnick; R. P. Bishop; C. E. Stevens

• Publisher: John Wiley and Sons
• Year: 1986
• Tongue: English
• Weight: 720 KB
• Volume: 20
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1890200208

✦ Synopsis

Strain CR326F of hepatitis A virus, derived from a fecal specimen of Costa Rican patient 033-03, was passed 15 times in fetal rhesus monkey kidney (FRhK6) cell cultures plus eight times in human diploid lung (MRC5) cell cultures to yield variant F and 16 times in MRC5 cell cultures to yield variant F'. Both variants were purified by limit dilution passages. Virulence for marmosets was assessed at six different passage levels, including variants F and F'. There was a gradual loss of virulence with in vitro passage. Variant F retained slight virulence for marmosets; variant F' showed no evidence of virulence. Both variants induced hepatitis A antibody in most marmosets that received them, and the animals were immune to infection when challenged. Variants F and F' were also assessed in chimpanzees. As in marmosets, F retained slight virulence but F' did not. Experimental vaccines made from variants F and F' were then inoculated parenterally into adult human volunteers. A portion of recipients of variant F showed brief, low-order enzyme elevations; none was seen in recipients of F', although their occurrence could not be totally ruled out. As in the animal models, F' appeared more attenuated than F. Most persons developed hepatitis A antibody, indicating the feasibility of developing a live, attenuated hepatitis A vaccine for human beings.